Literature DB >> 29531897

Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer.

Wan Ling Tan1, Daniel S W Tan1,2,3.   

Abstract

Entities:  

Year:  2018        PMID： 29531897      PMCID： PMC5835622          DOI： 10.21037/tlcr.2017.11.12

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  25 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

Authors:  Eiki Ichihara; Katsuyuki Hotta; Naoyuki Nogami; Shoichi Kuyama; Daizo Kishino; Masanori Fujii; Toshiyuki Kozuki; Masahiro Tabata; Daijiro Harada; Kenichi Chikamori; Keisuke Aoe; Hiroshi Ueoka; Shinobu Hosokawa; Akihiro Bessho; Akiko Hisamoto-Sato; Toshio Kubo; Isao Oze; Nagio Takigawa; Mitsune Tanimoto; Katsuyuki Kiura
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

4.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

5.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

Review 6.  Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.

Authors:  L Sorber; K Zwaenepoel; V Deschoolmeester; P E Y Van Schil; J Van Meerbeeck; F Lardon; C Rolfo; P Pauwels
Journal:  Lung Cancer       Date:  2016-05-04       Impact factor: 5.705

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.

Authors:  Yang Liu; Li Sun; Zhi-Cheng Xiong; Xin Sun; Shu-Ling Zhang; Jie-Tao Ma; Cheng-Bo Han
Journal:  Onco Targets Ther       Date:  2017-04-24       Impact factor: 4.147

9.  Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Authors:  George N Naumov; Monique B Nilsson; Tina Cascone; Alexandra Briggs; Oddbjorn Straume; Lars A Akslen; Eugene Lifshits; Lauren Averett Byers; Li Xu; Hua-Kang Wu; Pasi Jänne; Susumu Kobayashi; Balazs Halmos; Daniel Tenen; Xi M Tang; Jeffrey Engelman; Beow Yeap; Judah Folkman; Bruce E Johnson; John V Heymach
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

10.  Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Authors:  Amit Jain; Cindy Lim; Eugene MingJin Gan; David Zhihao Ng; Quan Sing Ng; Mei Kim Ang; Angela Takano; Kian Sing Chan; Wu Meng Tan; Ravindran Kanesvaran; Chee Keong Toh; Chian Min Loo; Anne Ann Ling Hsu; Anantham Devanand; Chong Hee Lim; Heng Nung Koong; Tina Koh; Kam Weng Fong; Swee Peng Yap; Su Woon Kim; Balram Chowbay; Lynette Oon; Kiat Hon Lim; Wan Teck Lim; Eng Huat Tan; Daniel Shao Weng Tan
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240
View more
  1 in total

1.  Lung cancer A549 cells suppressed with overexpressed HNF1B or PCDHA13 inhibited PI3K/AKT phosphorylation.

Authors:  Chunyan Kang; Lingxiao Wang; Dandan Wang; Xiuzhi Zhang; Jie Chen
Journal:  Transl Cancer Res       Date:  2020-06       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.